Latest news and press releases about Cerus Corporation (CERS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
Price
| Price | $2.53 |
| Market Cap | $510M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.88 |
| EV / EBITDA | 192.78 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.31% |
| Return on Invested Capital | -1.06% |
| Return on Assets | -3.31% |
| Gross Margin | 52.05% |
| Operating Margin | -0.73% |
| Net Margin | -3.06% |
Related companies: CVRX · MASS · NPCE · QTRX · RXST · SENS · SGHT
Explore sector: Healthcare · Medical - Devices
More sections of CERS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks